YES1 and breast cancer: In identifiable subsets of basal-like and HER2+ breast cancers, Bilal et al. suggested that several Src proto-oncogenes, including Lyn, Yes, Hck, Fyn, and Lck, were overexpressed and could serve as promising therapeutic targets because of their high degree of connectivity in the tumor network [64].